Boston Scientific Announces Schedule for European Society of Cardiology Congress
27 Agosto 2009 - 3:01PM
PR Newswire (US)
NATICK, Mass., Aug. 27 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE:BSX) today announced the schedule of the
Company's major events and news announcements for the European
Society of Cardiology (ESC) Congress, which runs from August 29 to
September 2 in Barcelona. Highlights include final results from the
MADIT-CRT trial and two-year results from the SYNTAX trial. "Boston
Scientific is proud to be the exclusive sponsor of the landmark
MADIT-CRT trial, and we look forward to the presentation of the
final data at ESC," said Ray Elliott, President and Chief Executive
Officer of Boston Scientific. "MADIT-CRT is breaking new ground by
demonstrating that early intervention with cardiac
resynchronization defibrillation therapy (CRT-D) slows the
progression of heart failure when compared to standard implantable
cardioverter defibrillator (ICD) therapy. We are also looking
forward to the presentation of two-year data from our SYNTAX trial,
comparing the use of percutaneous coronary intervention (PCI) using
the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System to
coronary artery bypass graft (CABG) surgery in patients with
complex disease. We are hopeful these results will build on the
one-year data, which showed comparable safety outcomes for PCI and
CABG." Details of the Company's activities at ESC are below.
Schedule of Events (All times are local Barcelona; all events are
held at the Fira Gran Via Convention Center.) Sunday, August 30 --
HORIZONS-AMI Trial Results. One-year data from the HORIZONS-AMI
trial will be presented in a poster session at 8:30 a.m. The trial
was designed to determine the safety and efficacy of the TAXUS
Express2 Paclitaxel-Eluting Coronary Stent System compared to
bare-metal stenting in patients experiencing an acute myocardial
infarction (AMI). Results will focus on the relative impact of
ischemic complications and varying definitions of major bleeding on
one-year mortality in patients with AMI. Monday, August 31 --
Clinical Seminar - The SYNTAX Trial: One Year On. The Company will
sponsor a clinical seminar chaired by Miguel Sousa Uva, M.D., and
Antonio Colombo, M.D., from 4:30-6:00 p.m. in the Madrid Room.
Discussion topics will include the view of the non-interventional
cardiologist and conclusions from subgroup analyses. Tuesday,
September 1 -- MADIT-CRT Trial Data. Final results from the
MADIT-CRT trial will be presented by Arthur Moss, M.D., during a
Hot Line presentation session at 12:15 p.m. in the Barcelona Room.
The MADIT-CRT trial has more than 1,800 patients and examines
whether early intervention with cardiac resynchronization therapy
in high-risk, New York Heart Association Class I and II patients
slows the progression of heart failure when compared to implantable
cardioverter defibrillator (ICD) therapy. The Company plans to
issue a press release simultaneous with an ESC press conference,
which begins at 8:00 a.m. -- Analyst Conference Call. The Company
will webcast a conference call beginning at 2:00 p.m. to discuss
final results from the MADIT-CRT trial. The live webcast and
archived replay of this call will be available at
http://www.bostonscientific.com/ in the Investor Relations section.
The webcast is also being distributed over Thomson Financial's
Investor Distribution Network via two locations:
http://www.earnings.com/, which is accessible to the public, and
http://www.streetevents.com/, a password-protected event management
site. -- PreSCD II Registry Data. Final results of the PreSCD II
registry will be presented by Heinz Voeller, M.D., during a Hot
Line presentation session at 12:00 p.m. in the Barcelona Room. The
PreSCD registry has enrolled 10,000 post-myocardial infarction
patients in 19 centers in Germany with follow-up to 36 months. The
study was designed to identify patients at risk of sudden cardiac
death and to evaluate the use of ICD therapy. The Company plans to
issue a press release at this time. -- Lunch Workshop - Device
Therapy in Treating Heart Failure. The Company will sponsor a lunch
workshop from 12:45-1:30 p.m. in the Belgrade Room titled "The ever
growing role of device therapy in the treatment of heart failure,"
chaired by Dr. Moss and Pedro Brugada Terradellas, M.D. The
workshop will explore new approaches to managing the progression of
heart failure and the role of remote patient management. --
Satellite Symposium - Tackling Complex Coronary Disease. The
Company will sponsor a satellite symposium titled "Tackling complex
coronary disease anno 2009: scientific and technological progress,"
chaired by Stephan Windecker, M.D., and Keith Dawkins, M.D., from
2:00-3:30 p.m. in the Belgrade Room. Discussion topics will include
the evolution of drug-eluting stents, the promise of new stent
technology and case a study with a new stent platform. Boston
Scientific's new Element(TM) Stent platform will be featured, along
with other new technologies. Wednesday, September 2 -- SYNTAX Study
Update. Two-year outcomes data from the SYNTAX trial will be
presented by A. Pieter Kappetein, M.D., at 9:15 a.m. during a
Clinical Trial Update session in the Barcelona Room. SYNTAX is the
first randomized, controlled clinical trial comparing PCI using
drug-eluting stents to CABG surgery in patients with left main
and/or three-vessel disease. The Company plans to issue a press
release at this time. Boston Scientific will present its latest
innovations at booth C99 in the Exhibition Hall. Cardiovascular and
cardiac rhythm management products will include the LATITUDE
Patient Management System, which was recently launched in Europe,
and the Company's third-generation drug-eluting stents: the TAXUS
Element(TM) Paclitaxel-Eluting Coronary Stent System and the PROMUS
Element(TM) Everolimus-Eluting Coronary Stent System. The Company
is still expecting CE Mark approval and launch for both the TAXUS
Element and the PROMUS Element Stent Systems in the fourth quarter
of this year. The TAXUS Element and PROMUS Element Stent Systems
are not available for sale in the United States. The safety and
effectiveness of the TAXUS Express Stent has not been established
in patients with left main or three-vessel disease. Boston
Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please
visit: http://www.bostonscientific.com/. Cautionary Statement
Regarding Forward-Looking Statements This press release contains
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are
not intended to be guarantees of future events or performance.
These forward-looking statements include, among other things,
statements regarding clinical trials, scientific activities, and
product performance. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements. Factors that may
cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item IA- Risk Factors in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors
in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly
update or revise any forward-looking statements to reflect any
change in our expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document. CONTACT: Paul Donovan 508-650-8541 (office)
508-667-5165 (mobile) Media Relations Boston Scientific Corporation
Larry Neumann 508-650-8696 (office) Investor Relations Boston
Scientific Corporation DATASOURCE: Boston Scientific Corporation
CONTACT: Media Relations, Paul Donovan, +1-508-650-8541 (office),
+1-508-667-5165 (mobile); or Investor Relations, Larry Neumann,
+1-508-650-8696 (office), both of Boston Scientific Corporation Web
Site: http://www.bostonscientific.com/
Copyright